关键词： 阿斯利康 Alchemia
2013年4月23日讯 /生物谷BIOON/ --Alchemia公司今天宣布，已与阿斯利康（AstraZeneca）达成了一项多靶标药物发现合作协议，所涉及的疾病横跨多个领域，包括肿瘤、呼吸、心血管、代谢、感染及神经科学。
该项合作中，Alchemia将利用专有的多样性扫描阵列（DSA）和相关的稳定模板多功能装配（VAST）化学平台，来发现及开发针对阿斯利康所提供多个靶标的新颖小分子。
根据协议条款，Alchemia将获得一笔未披露金额的预付款，同时将有资格获得高达2.4亿的里程碑款项及所合作产品在未来销售的特许权使用费。（生物谷bioon.com）
英文原文：
Brisbane, Australia 23 April 2013 – Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca AB (AstraZeneca).
This collaboration includes the use of the proprietary Diversity Scanning Array (DSA) and associated Versatile Assembly on Stable Templates (VAST) chemistry platform to discover and develop novel small molecules against multiple AstraZeneca targets. Alchemia will provide VAST chemistry expertise to develop small molecule clinical candidates for AstraZeneca. By accessing Alchemia’sVAST discovery platform, AstraZeneca will seek novel small molecules to treat diseases across a variety of therapeutic areas including oncology, respiratory, cardiovascular, metabolism, infection and neuroscience.
“We are excited to work alongside AstraZeneca’s teams to explore the applications of our proprietary VAST technology against a range of targets,” said Dr. Wim Meutermans, VP of Discovery at Alchemia and co-inventor of the VAST platform.“This collaboration has the potential to demonstrate the unique capabilities and value of VAST and is a pivotal step in the commercialization of both the DSA and the VAST platform. I look forward to developing a strong and productive alliance with AstraZeneca over the coming years.”
“Alchemia’s DSA library and expertise in carbohydrate chemistry are welcome additions to our small molecule corporate collection and early discovery hit finding activities,” said Mike Snowden, Head of Discovery Sciences at AstraZeneca. “We are looking forward to working with Alchemia to maximise the potential of this novel platform in early phase drug discovery at AstraZeneca.”Under the terms of this Agreement, Alchemia will receive an undisclosed upfront payment and iseligible for potential preclinical, clinical and commercial launch payments totalling up to $240M, as well as a single digit royalty
(责任编辑：yan.mao)
